Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.45 |
| ▸ | NPY1R | P25929 | 9/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.45 |
| ▸ | NPY2R | P49146 | 5/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31391112 | 0.94 | PTGS1 (0.46) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL31391109 | 0.92 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30642367 | 0.90 | PTGS1 (0.46) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30929978 | 0.88 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL29696186 | 0.88 | SIRT5 (0.50) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL30148051 | 0.88 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL29412493 | 0.88 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL29630450 | 0.88 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL23286096 | 0.88 | NOD1 (0.50) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL1711608 | 0.88 | NOD1 (0.50) | NPY4RNPY1RNPY5RNPY2RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302981-A1 | NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302981-A1 | NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE | KRAS, TP53, NRAS | NPY4R 4845/4885NPY1R 4861/4885NPY5R 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.